Excluding the ribosome and riboswitches, developing small molecules that selectively target RNA is a longstanding problem in chemical biology. A typical cellular RNA is difficult to target because it has little tertiary, but abundant secondary structure. We designed allele-selective compounds that target such an RNA, the toxic noncoding repeat expansion (r(CUG)exp) that causes myotonic dystrophy type 1 (DM1). We developed several strategies to generate allele-selective small molecules, including non-covalent binding, covalent binding, cleavage and on-site probe synthesis. Covalent binding and cleavage enabled target profiling in cells derived from individuals with DM1, showing precise recognition of r(CUG)exp. In the on-site probe synthesis approach, small molecules bound adjacent sites in r(CUG)exp and reacted to afford picomolar inhibitors via a proximity-based click reaction only in DM1-affected cells. We expanded this approach to image r(CUG)exp in its natural context.
You may also like
The fruit fly and its comb-shaped neurons
February 1, 2021Ernst Strüngmann Institute for Neuroscience
Science on film, episode 4: Motivational states of the...
January 29, 2021Max Planck Institute for Biological Cybernetics
A small molecule involved in depression
January 29, 2021Max Planck Institute of Psychiatry
Max Planck Florida and Zeiss Announce Research...
January 13, 2021Max Planck Florida Institute for Neuroscience
New approach reveals structure and function of...
December 16, 2020Max Planck Florida Institute for Neuroscience
Targeting Functionally Characterized Synaptic...
December 15, 2020Max Planck Florida Institute for Neuroscience